Related references
Note: Only part of the references are listed.Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects
H. Jenkins et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis
K. Ashida et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Acid-inhibitory effects of vonoprazan 20mg compared with esomeprazole 20mg or rabeprazole 10mg in healthy adult male subjects - a randomised open-label cross-over study
Y. Sakurai et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Vonoprazan: First Global Approval
Karly P. Garnock-Jones
DRUGS (2015)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects
Yuuichi Sakurai et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2015)
Systematic Comparison of Molecular Conformations of H+,K+-ATPase Reveals an Important Contribution of the A-M2 Linker for the Luminal Gating
Kazuhiro Abe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Protonated Form: The Potent Form of Potassium-Competitive Acid Blockers
Hua-Jun Luo et al.
PLOS ONE (2014)
Discovery, synthesis, and biological evaluation of novel pyrrole derivatives as highly selective potassium-competitive acid blockers
Haruyuki Nishida et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
Discovery of a Novel Pyrrole Derivative 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Fumarate (TAK-438) as a Potassium-Competitive Acid Blocker (P-CAB)
Yasuyoshi Arikawa et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Characterization of a Novel Potassium-Competitive Acid Blocker of the Gastric H,K-ATPase, 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438)
Jai Moo Shin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Clinical trial: Inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects
Hyung-Keun Kim et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2010)
1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases
Yasunobu Hori et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
The gastric HK-ATPase: structure, function, and inhibition
Jai Moo Shin et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2009)
Acid peptic diseases: pharmacological approach to treatment
Alex Mejia et al.
Expert Review of Clinical Pharmacology (2009)
A Randomized, Comparative Trial of a Potassium-Competitive Acid blocker (AZD0865)and Esomeprazole for the Treatment of Patients With Nonerosive Reflux Disease
John Dent et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Molecular mechanisms in therapy of acid-related diseases
J. M. Shin et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2008)
Soraprazan: Setting new standards in inhibition of gastric acid secretion
W. A. Simon et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Analysis of the gastric H,K ATPase for ion pathways and inhibitor binding sites
Keith Munson et al.
BIOCHEMISTRY (2007)
Characteristics of the K+-competitive H+, K+-ATPase inhibitor AZD0865 in isolated rat gastric glands
P. Kirchhoff et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2006)
Inhibitor and ion binding sites on the gastric H,K-ATPase
K Munson et al.
BIOCHEMISTRY (2005)
The cavity structure for docking the K+-competitive inhibitors in the gastric proton pump
S Asano et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study
PO Katz et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
SCH28080, a K+-competitive inhibitor of the gastric H,K-ATPase, binds near the M5-6 luminal loop, preventing K+ access to the ion binding domain
O Vagin et al.
BIOCHEMISTRY (2002)
Effect of omeprazole on regional and temporal variations in intragastric acidity
F Viani et al.
DIGESTION (2002)
Share Paper
